SCULPTRA®

Why Healthcare Professionals Choose SCULPTRA®

SCULPTRA® is an FDA-approved poly-L-lactic acid (PLLA) collagen-stimulating filler from Galderma, used for gradual facial volume restoration and collagen-based improvement in facial wrinkles. Its PLLA microspheres stimulate collagen production through a controlled tissue response, producing gradual structural volume restoration over weeks to months. This makes SCULPTRA® clinically relevant for broader facial volume loss and structural collagen depletion, areas where HA fillers provide temporary correction but not biostimulation. The result is a product that functions as a complement to HA fillers in a practitioner's treatment portfolio rather than a direct substitute. [2] Its second differentiator is longevity. While many HA fillers last about 6–18 months, SCULPTRA® results may last up to 2 years after a full treatment course. For practices whose patients prefer sustained structural improvement over frequent maintenance visits, this duration supports both treatment planning and patient retention. [1]

Order SCULPTRA® at Wholesale Prices

Med Supply Solutions offers SCULPTRA® products to licensed medical professionals at wholesale prices, with reliable delivery, lot numbers provided for traceability, and fast shipping. Looking to buy SCULPTRA® online or source SCULPTRA® wholesale? Get in touch with the team at Med Supply Solutions for guidance on availability and account setup.

What Is SCULPTRA® Used For?

SCULPTRA® is used for facial volume restoration, shallow-to-deep wrinkles, facial fold correction, and collagen-stimulation protocols in patients with structural volume loss. It is made from poly-L-lactic acid (PLLA), a biocompatible, biodegradable material that works differently from hyaluronic acid fillers. Rather than providing immediate volumizing correction through gel placement, SCULPTRA® supports gradual collagen production through a controlled tissue response as PLLA microspheres are absorbed over time. [2] The result is a treatment suited to diffuse structural volume loss and age-related collagen depletion, where the goal is long-term remodeling rather than instant projection. Visible improvement typically appears over 4–6 weeks and continues to develop as collagen production increases. These make SCULPTRA® most appropriate for practitioners planning structural correction with patients willing to allow a gradual timeline.

The SCULPTRA® Product Range

The SCULPTRA® range is deliberately limited compared with HA filler portfolios, and that simplicity is part of its positioning. SCULPTRA® Aesthetic is FDA-approved for the correction of shallow-to-deep nasolabial fold contour deficiencies and other facial wrinkles in immunocompetent patients (2009 approval). The original SCULPTRA® formulation received FDA approval in 2004 for correction of HIV-associated facial lipoatrophy. Both share the same core technology: a powder vial containing 367.5 mg of PLLA microspheres, reconstituted with sterile water before use; lidocaine may also be added immediately before injection. [3][4] The reconstitution process is clinically relevant. Dilution, hydration timing, and injection technique all affect outcome consistency and nodule risk. One versatile PLLA biostimulator covering multiple facial zones is the deliberate clinical brief, rather than a product-per-indication approach.

SCULPTRA® Treatment Areas

SCULPTRA® is indicated for areas of age-related structural volume loss and is commonly used in clinical practice, including the temples, cheeks, jawline, nasolabial folds, marionette lines, and chin. It is best suited for broader contour support and collagen stimulation rather than fine superficial lines, where dermal fillers or targeted skin-quality injectables are more appropriate. [1] Off-label body use, including the widely discussed Sculptra butt lift, is a high-traffic search area. It remains an off-label application and should be evaluated in accordance with practitioner training, local regulations, and individual patient selection criteria.

SCULPTRA® vs Other Collagen Stimulators

Compared with HA fillers such as JUVÉDERM® or RESTYLANE®, SCULPTRA® occupies a distinct clinical role. HA fillers provide immediate correction, projection, or contour through gel placement, and many last about 6–18 months. SCULPTRA® provides no immediate volumizing effect and instead builds gradual structural improvement through collagen production — making it the more appropriate choice for diffuse volume loss and long-term structural remodeling, while HA fillers remain the tool of choice for precise shaping or immediate correction. [1] Compared with RADIESSE® fillers, SCULPTRA® differs in onset, material behavior, and patient profile. RADIESSE® uses calcium hydroxylapatite microspheres that provide immediate volume alongside delayed collagen stimulation, often presented as lasting around 12 months or longer depending on indication and technique. SCULPTRA® provides no immediate filler effect — all correction comes from progressive collagen production — making it better suited for patients comfortable with a gradual timeline and fewer long-term maintenance appointments. RADIESSE® may suit those who want both immediate and longer-term benefit from a single session. Neither is universally superior; appropriate selection depends on anatomy, correction goals, timeline expectations, and practitioner preference. SCULPTRA® also holds one of the longest regulatory histories among collagen-stimulating injectables in the US market, with FDA approval dating to 2004 for HIV-associated lipoatrophy and 2009 for aesthetic facial indications. [3]

About SCULPTRA®

SCULPTRA® was originally developed by Aventis Pharma in France and introduced in Europe in 1999 under the name New-Fill. It received FDA approval in 2004 under the SCULPTRA® name for HIV-associated facial lipoatrophy, with aesthetic facial indications added in 2009 as SCULPTRA® Aesthetic. Galderma acquired SCULPTRA® from Dermik Laboratories, a subsidiary of sanofi-aventis, in 2014 and now positions it within its injectable aesthetics portfolio as a collagen stimulator rather than a conventional filler. [3] At the core of every SCULPTRA® vial are PLLA microspheres with a narrow particle-size distribution, generally in the approximately 40–63 µm range, suspended in a carboxymethylcellulose (CMC) carrier after reconstitution with sterile water. [4] These microspheres are gradually absorbed over several months while the collagen they stimulated can persist for up to 2 years — a distinction between particle resorption and collagen persistence that is central to understanding SCULPTRA®'s mechanism and patient selection rationale. [2]

SCULPTRA® Safety Profile

SCULPTRA® side effects are primarily related to injection and product placement. Common reactions may include redness, swelling, bruising, tenderness, pain, itching, bleeding, or temporary lumps at the injection site. Rare reactions may include persistent nodules, infection, delayed inflammation, or granuloma-like responses. [1] Nodule risk is technique-dependent and associated with improper injection depth, inadequate dilution, uneven product placement, or insufficient post-treatment massage. The 5-5-5 massage protocol involves massaging the treated area 5 times a day, for 5 minutes each time, for 5 days post-injection. It is a commonly recommended post-treatment massage approach and should be communicated at consultation. SCULPTRA® is contraindicated in patients with known hypersensitivity to any formulation component, and caution is required in patients with autoimmune conditions or during pregnancy and breastfeeding.

How Long Does SCULPTRA® Last?

Initial injection-related swelling resolves within 1–2 days, while collagen production becomes progressively more visible over 4–6 weeks. Full results are typically assessed over 3–6 months after completing an initial treatment course, which commonly involves 2–3 sessions spaced 4–6 weeks apart. Results may last up to 2 years, with factors including patient age, baseline skin condition, number of initial sessions, and lifestyle affecting individual duration. Maintenance or touch-up sessions at around 12–18 months are considered in some treatment plans to extend results. [1][2]

SCULPTRA® Administration

• SCULPTRA® is supplied as a PLLA powder that must be reconstituted with sterile water 24–72 hours before use — a handling requirement with practical implications for ordering, storage, and session scheduling; lidocaine may be added immediately before injection. [4]
• It is placed subdermally in appropriate facial zones, with injection depth and product distribution guided by anatomy, treatment goal, and current prescribing information.
• Post-treatment massage following the 5-5-5 protocol is a commonly recommended approach to promote even distribution and reduce nodule risk.

SCULPTRA® Regulatory Status

SCULPTRA® received FDA approval on August 3, 2004, for the restoration or correction of facial lipoatrophy in HIV-positive patients, and SCULPTRA® Aesthetic received FDA approval on July 28, 2009, for the correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in immunocompetent patients where deep dermal grid-pattern injection is appropriate. [3] SCULPTRA® is also CE-marked in Europe (previously approved under the New-Fill name from 1999) and is available across multiple international markets. Manufacturing is conducted by Galderma under GMP standards.

FAQs

1. What is SCULPTRA® and how does it work?

SCULPTRA® is a poly-L-lactic acid (PLLA) biostimulator, not an HA filler. Its microspheres stimulate collagen production through a controlled tissue response, producing gradual structural volume improvement over weeks to months rather than immediate filler-based correction. [2]

2. How many SCULPTRA® sessions are typically needed?

Most initial treatment plans involve 2–3 sessions spaced approximately 4–6 weeks apart, though the exact number depends on the degree of volume loss, treatment area, and clinical response. Maintenance or touch-up sessions around 12–18 months are considered in some plans to sustain results.

3. How long does SCULPTRA® last compared to other fillers?

SCULPTRA® may last up to 2 years after a full treatment course. By comparison, many HA fillers last about 6–18 months, and RADIESSE® is often presented as lasting around 12 months or longer depending on indication and technique.

4. What areas can SCULPTRA® treat?

SCULPTRA® is commonly used for the temples, cheeks, jawline, nasolabial folds, marionette lines, and chin. Off-label body applications, including buttock augmentation, are discussed in aesthetic practice but should be approached in accordance with practitioner training, local regulations, and individual patient selection.

5. What is the difference between SCULPTRA® and SCULPTRA® Aesthetic?

SCULPTRA® was originally FDA-approved in 2004 for HIV-associated facial lipoatrophy. SCULPTRA® Aesthetic received FDA approval in 2009 for cosmetic facial indications, including nasolabial fold contour deficiencies and other facial wrinkles in immunocompetent patients. Both use the same PLLA formulation; the difference is the approved indication.

6. Can SCULPTRA® nodules be prevented?

Nodule risk can be substantially reduced with proper dilution, correct injection depth, even product distribution, and consistent post-treatment massage. The 5-5-5 massage protocol — 5 times daily, 5 minutes each, for 5 days post-injection — is a commonly recommended approach for post-treatment management.

7. Where can licensed professionals buy SCULPTRA® online?

Licensed professionals looking to buy SCULPTRA® online can contact the Med Supply Solutions team for guidance on availability, documentation, account setup, and procurement requirements.

Citations

1. Fabi S, Hamilton T, LaTowsky B, et al. Effectiveness and Safety of Sculptra Poly-L-Lactic Acid Injectable Implant in the Correction of Cheek Wrinkles. J Drugs Dermatol. 2024;23(1):1297-1305. doi:36849/JDD.7729
2. Avelar LET, Yan X, Bråsäter D. Comprehensive Systematic Review of Poly-L-Lactic Acid in Facial Clinical Application. Aesthetic Plast Surg. 2025;49(23):6798-6800. doi:10.1007/s00266-025-05030-4
3. United States Food and Drug Administration. Sculptra – P030050/S039. FDA website. Published September 7, 2024. https://www.fda.gov/medical-devices/recently-approved-devices/sculptra-p030050s039
4. Galderma Australia. Sculptra® Poly-L-lactic acid. Instructions for use. August 2021. https://www.galderma.com/au/sites/default/files/Sculptra%20IFU_Aug21.pdf

For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.